logo
Share SHARE
FONT-SIZE Plus   Neg

Par Pharmaceutical Closed Acquisition Of Privately Held Edict - Quick Facts

Generic drug maker Par Pharmaceutical Companies Inc. (PRX: Quote) said Friday it has completed the acquisition of privately-held Edict Pharmaceuticals Private Limited.

Par, based in New Jersey, said it paid $20.5 million at closing and $4.4 million repayment of certain pre-close indebtedness.

India-based Edict is a developer and manufacturer of solid oral dosage generic pharmaceuticals company, and currently has 11 ANDAs filed with the U.S. FDA.

In connection with the closing of the deal, a lawsuit by a former shareholder of Edict, Gavis Pharma LLC, was settled by the payment of a portion of the closing proceeds to Gavis by an Edict shareholder.

Par Pharmaceutical Companies Inc., is through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, develops high barrier-to-entry generic drugs and innovative proprietary pharmaceuticals.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Automakers on Friday reported higher U.S. vehicle sales for the month of April, helped by low gasoline prices as well as continuing strong demand for trucks and utility vehicles. General Motors Co. and FCA US, LLC each reported sales growth of about 6% for the month, while Ford Motor Co. and Toyota Motor Corp. reported 5.4% and 1.8% increases, respectively. Are you really ready for an objective appraisal of how old you look? If not, stay far away from How-Old.net, a website to guess how old you are, which was introduced at the recent Microsoft Build 2015 developer conference. The website has caught... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its first quarter loss widened from last year, as higher costs and expenses more than offset a 35% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
Follow RTT